SkyePharma on target for full year

Drug development firm SkyePharma said expectations for 2012 pre-exceptional operating profit remain unchanged and is confident of future trading as it launches its asthma treatment product flutiform across Europe.

Drug development firm SkyePharma said expectations for 2012 pre-exceptional operating profit remain unchanged and is confident of future trading as it launches its asthma treatment product flutiform across Europe.

SkyePharma cautioned that some contract development work has been delayed into 2013 but the effect is expected to be offset by lower costs.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.